| Literature DB >> 34400042 |
Angela C Weyand1, Veronica H Flood2.
Abstract
Von Willebrand disease (VWD) is a common bleeding disorder, affecting male and female individuals equally, that often manifests in mucosal bleeding. VWD can be secondary to a quantitative (Type 1 and Type 3) or qualitative (Type 2) defects in Von Willebrand factor (VWF). Initial testing includes VWF antigen, as well as a platelet binding assay to differentiate between qualitative and quantitative defects. Further subtyping requires additional testing and is needed to ensure appropriate treatment. Desmopressin, antifibrinolytics, hormonal treatments for heavy menstrual bleeding, and VWF concentrates are commonly used in the treatment of VWD.Entities:
Keywords: Bleeding; Coagulation factors; von Willebrand disease; von Willebrand factor
Mesh:
Substances:
Year: 2021 PMID: 34400042 PMCID: PMC8919990 DOI: 10.1016/j.hoc.2021.07.004
Source DB: PubMed Journal: Hematol Oncol Clin North Am ISSN: 0889-8588 Impact factor: 3.722